Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo

References

• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462.30970190
   PubMed Web of Science ®Google Scholar
• Dawkins J, Webster RM. The hepatocellular carcinoma market. Nat Rev Drug Discov. 2018;18(1):13–14. doi:10.1038/nrd.2018.14630168534
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Kim YS, Shin SW. Hepatocellular carcinoma. N Engl J Med. 2019;381(1):e2.
   PubMedGoogle Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Cancer Immunother. 2018;359(6382):1361–1365.
   Google Scholar
• Lv J, Zhao R, Wu D, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12(1):18. doi:10.1186/s13045-019-0704-y30777106
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12(1):126. doi:10.1186/s13045-019-0817-331779642
   PubMed Web of Science ®Google Scholar
• Heymach J, Krilov L, Alberg A, et al. Clinical cancer advances 2018: annual report on progress against cancer from the american society of clinical oncology. J clin oncol. 2018;36(10):1020–1044. doi:10.1200/JCO.2017.77.044629380678
   PubMed Web of Science ®Google Scholar
• Han J, Gao F, Geng S, et al. Minicircle DNA-engineered CAR T cells suppressed tumor growth in mice. Mol Cancer Ther. 2020;19(1):178–186. doi:10.1158/1535-7163.MCT-19-020431582530
   PubMed Web of Science ®Google Scholar
• Deng X, Gao F, Li N, et al. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo. Am J Cancer Res. 2019;9(5):945–958.31218103
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. doi:10.1016/j.immuni.2019.12.01131940268
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66(19):9339–9344. doi:10.1158/0008-5472.CAN-06-312616990346
   PubMedGoogle Scholar
• Ruiu R, Tarone L, Rolih V, et al. Cancer stem cell immunology and immunotherapy: harnessing the immune system against cancer’s source. 2019;164:119–188.
   Google Scholar
• Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–267. doi:10.1038/nrc302321390059
   PubMed Web of Science ®Google Scholar
• Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133+CD44+/high tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2011;22(1):259–272. doi:10.1038/cr.2011.13921862973
   PubMed Web of Science ®Google Scholar
• Chen Z-Y, He C-Y, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther. 2003;8(3):495–500. doi:10.1016/S1525-0016(03)00168-012946323
   PubMed Web of Science ®Google Scholar
• Zhao J, Huang P, Wang Z, et al. Synthesis of amphiphilic poly(β-amino ester) for efficiently minicircle DNA delivery in vivo. ACS Appl Mater Interfaces. 2016;8(30):19284–19290. doi:10.1021/acsami.6b0441227267084
   PubMed Web of Science ®Google Scholar
• Wei X, Ma H ScFv against cancer stem cell specific protein CD44 and its applications. Chinese Patent. No. 103288958.
   Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa140722225317870
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138–177ra138. doi:10.1126/scitranslmed.3005930
   Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase 1 dose-escalation trial. The Lancet. 2015;385(9967):517–528. doi:10.1016/S0140-6736(14)61403-3
   PubMed Web of Science ®Google Scholar
• Abreu TR, Fonseca NA, Gonçalves N, Moreira JN. Current challenges and emerging opportunities of CAR-T cell therapies. J Controlled Release. 2020;319:246–261. doi:10.1016/j.jconrel.2019.12.047
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Z, Yang Z, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers. Mol Ther. 2017;25(5):1248–1258. doi:10.1016/j.ymthe.2017.03.01028366766
   PubMed Web of Science ®Google Scholar
• Jiang H, Gao H, Kong J, et al. Selective targeting of glioblastoma with EGFRvIII/EGFR bitargeted chimeric antigen Receptor T cell. Cancer Immunol Res. 2018;6(11):1314–1326. doi:10.1158/2326-6066.CIR-18-004430201736
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin Cancer Res. 2019;25(9):2915–2924. doi:10.1158/1078-0432.CCR-18-181130617136
   PubMed Web of Science ®Google Scholar
• Zhou R, Yazdanifar M, Roy LD, et al. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 2019;10:1149. doi:10.3389/fimmu.2019.0114931178870
   PubMed Web of Science ®Google Scholar
• Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014;20(24):6418–6428. doi:10.1158/1078-0432.CCR-14-117025320357
   PubMed Web of Science ®Google Scholar
• Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128. doi:10.3389/fimmu.2019.0012830804938
   PubMed Web of Science ®Google Scholar
• Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15(11):669–682. doi:10.1038/nri390226471778
   PubMed Web of Science ®Google Scholar
• Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm. 2011;8(3):635–641. doi:10.1021/mp100422821545153
   PubMed Web of Science ®Google Scholar
• van den Beucken T, Koch E, Chu K, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014;5(1):5203. doi:10.1038/ncomms620325351418
   PubMedGoogle Scholar
• Jeong H, Kim S, Hong B-J, et al. Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis. Cancer Res. 2019;79(4):795–806. doi:10.1158/0008-5472.CAN-18-254530610087
   PubMed Web of Science ®Google Scholar
• Najafi M, Farhood B, Mortezaee K, Kharazinejad E, Majidpoor J, Ahadi R. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance. J Cancer Res Clin Oncol. 2019;146(1):19–31. doi:10.1007/s00432-019-03080-131734836
   PubMed Web of Science ®Google Scholar
• Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15(6):501–513. doi:10.1016/j.ccr.2009.03.01819477429
   PubMed Web of Science ®Google Scholar
• Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524–529. doi:10.1038/nm.383325849134
   PubMed Web of Science ®Google Scholar
• Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial–mesenchymal transition and cancer development. Onco Targets Ther. 2015;8:3783–3792. doi:10.2147/OTT.S9547026719706
   PubMed Web of Science ®Google Scholar
• Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64. doi:10.1186/s13045-018-0605-529747682
   PubMed Web of Science ®Google Scholar
• Rodrigo JP, Domínguez F, Alvarez C, González MV, Herrero A, Suárez C. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002;118(1):67–72. doi:10.1309/F50H-6MLG-R7LM-2XFT12109858
   PubMed Web of Science ®Google Scholar
• Spring FA, Dalchau R, Daniels GL, et al. The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology. 1988;64(1):37–43.2454887
   PubMed Web of Science ®Google Scholar
• Yin T, Wang G, He S, Liu Q, Sun J, Wang Y. Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cell Immunol. 2016;300:41–45. doi:10.1016/j.cellimm.2015.11.00926677760
   PubMed Web of Science ®Google Scholar
• Banerjee S, Modi S, McGinn O, et al. Impaired synthesis of stromal components in response to minnelide improves vascular function, drug delivery, and survival in pancreatic cancer. Clin Cancer Res. 2015;22(2):415–425. doi:10.1158/1078-0432.CCR-15-115526405195
   PubMed Web of Science ®Google Scholar
• Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 1997;4(12):1341–1349. doi:10.1038/sj.gt.33005409472558
   PubMed Web of Science ®Google Scholar